Log in

NYSEAMERICAN:ATNMActinium Pharmaceuticals Stock Price, Forecast & News

-0.11 (-1.14 %)
(As of 08/13/2020 04:00 PM ET)
Today's Range
Now: $9.55
50-Day Range N/A
52-Week Range
Now: $9.55
Volume749,400 shs
Average Volume397,533 shs
Market Capitalization$129.61 million
P/E RatioN/A
Dividend YieldN/A
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
Read More
Actinium Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Market Cap$129.61 million
Next Earnings Date8/14/2020 (Estimated)
-0.11 (-1.14 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Actinium Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Actinium Pharmaceuticals

When is Actinium Pharmaceuticals' next earnings date?

Actinium Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Actinium Pharmaceuticals

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) released its quarterly earnings results on Monday, June, 29th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.69) by $0.21.
View Actinium Pharmaceuticals' earnings history

When did Actinium Pharmaceuticals' stock split? How did Actinium Pharmaceuticals' stock split work?

Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of Actinium Pharmaceuticals stock prior to the reverse split would have 3 shares after the split.

Has Actinium Pharmaceuticals been receiving favorable news coverage?

News headlines about ATNM stock have trended negative on Friday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Actinium Pharmaceuticals earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Actinium Pharmaceuticals

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 5,830,000 shares, an increase of 120.0% from the June 15th total of 2,650,000 shares. Based on an average trading volume of 15,000,000 shares, the days-to-cover ratio is currently 0.4 days.
View Actinium Pharmaceuticals' Short Interest

Who are some of Actinium Pharmaceuticals' key competitors?

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Fitbit (FIT), OHR Pharmaceutical (OHRP), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), Opko Health (OPK), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE) and AEterna Zentaris (AEZS).

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the following people:
  • Mr. Sandesh C. Seth, Chairman & CEO (Age 55)
  • Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)
  • Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Mark S. Berger, Chief Medical Officer (Age 64)
  • Mr. Anil Kapur, Chief Commercial Officer (Age 50)

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (0.19%), Virtu Financial LLC (0.17%), Oxford Financial Group Ltd. (0.03%), ETRADE Capital Management LLC (0.59%), UBS Group AG (0.02%) and Laidlaw Wealth Management LLC (0.15%). Company insiders that own Actinium Pharmaceuticals stock include Dale L Ludwig and Steve O'loughlin.
View institutional ownership trends for Actinium Pharmaceuticals

Which major investors are selling Actinium Pharmaceuticals stock?

ATNM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Actinium Pharmaceuticals

Which major investors are buying Actinium Pharmaceuticals stock?

ATNM stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Virtu Financial LLC, Oxford Financial Group Ltd., ETRADE Capital Management LLC, and Laidlaw Wealth Management LLC. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Dale L Ludwig, and Steve O'loughlin.
View insider buying and selling activity for Actinium Pharmaceuticals

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $9.55.

How big of a company is Actinium Pharmaceuticals?

Actinium Pharmaceuticals has a market capitalization of $129.61 million. Actinium Pharmaceuticals employs 30 workers across the globe.

What is Actinium Pharmaceuticals' official website?

The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.